Figure 3 | Scientific Reports

Figure 3

From: The novel adamantane derivatives as potential mediators of inflammation and neural plasticity in diabetes mice with cognitive impairment

Figure 3

Treatment with novel adamantane derivatives (2, 3) or drugs—vildagliptin and saxagliptin attenuates memory impairment in induced diabetic mice in Y Maze Novelty Preference test (NPT). The dotted line at 0.5 indicates the chance performance value. Scores greater than 0.5 indicate a novelty preference. Bars in figure illustrates experimental groups—CTL non-diabetic mice, DM diabetic mice, DM-Vil vildagliptin-treated mice [20 mg/kg, po], DM-Sax saxagliptin-treated mice [10 mg/kg, po], DM-compound 2 compound 2-treated mice [50 mg/kg, po], DM-compound 3 compound 3-treated mice [50 mg/kg, po]; respectively. Each column represent means ± SD (n = 8). One-way ANOVA, followed by Tukey's post hoc test was used. *p < 0.05 as compared with healthy control group. #p < 0.05; ##p < 0.01 compared with diabetic mice group.

Back to article page